PMID: 6168923Aug 1, 1981Paper

Release of histamine by substance P

Naunyn-Schmiedeberg's Archives of Pharmacology
F ErjavecP Holzer

Abstract

1. The basic peptide substance P causes histamine release from peritoneal mast cells of the rat in vitro whereas the closely related neutral peptides eledoisin and physalaemin do not. 2. Infusion of substance P (7.4 nmol min-1), but not of eledoisin (8.4 nmol min-1) or physalaemin (7.9 nmol min-1), into the rat hindquarter preparation caused a more than 4-fold increase of the histamine content in the venous outflow. The outflow of 5-HT remained unchanged under infusion of all three peptides. 3. No histamine depletion in the skin of the rat hind paw was observed following antidromic stimulation of the saphenous nerve or cutaneous application of mustard oil. Infusion of substance P (7.4 nmol min-1) caused a 47% depletion of histamine in the paw skin although only a small proportion of the infused substance P seemed to enter the tissue from the blood vessels. 4. The results further substantiate the view that substance P upon release from peripheral nerve endings induces release of histamine from cutaneous mast cells, a mechanism which contributes to neurogenic vasodilatation and plasma extravasation.

References

Jan 31, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·N MayerR Gamse
Oct 1, 1978·The Journal of Investigative Dermatology·O HägermarkB Pernow
Dec 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·F Lembeck, P Holzer
Dec 1, 1977·Acta Physiologica Scandinavica·L OlgartG Nilsson
Jul 1, 1979·Acta Physiologica Scandinavica·A BillG Nilsson
Jan 1, 1977·British Journal of Pharmacology·P T ArvierR J Ladd
Oct 1, 1978·Naunyn-Schmiedeberg's Archives of Pharmacology·F LembeckR Gamse
Apr 1, 1975·Quarterly Journal of Experimental Physiology and Cognate Medical Sciences·J A Kiernan
Apr 1, 1973·Proceedings of the Society for Experimental Biology and Medicine·A R Johnson, E G Erdös
Jan 1, 1969·Naunyn-Schmiedebergs Archiv Für Pharmakologie·F Geipert, F Lembeck
Apr 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·F Lembeck, J Donnerer
Nov 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·C R Morton, L A Chahl
Oct 1, 1955·Proceedings of the Society for Experimental Biology and Medicine·E P BENDITTE ROEPER
Jun 1, 1956·British Journal of Pharmacology and Chemotherapy·B K BHATTACHARYA, G P LEWIS
Jul 11, 1957·The Journal of Physiology·J R PARRATT, G B WEST
Jul 11, 1957·The Journal of Physiology·J R PARRATT, G B WEST
Sep 5, 1958·Annals of the New York Academy of Sciences·E P BENDITT
Feb 16, 1965·Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie·B UVNAES
Oct 29, 1951·The Journal of Physiology·W W DOUGLASM SCHACHTER

❮ Previous
Next ❯

Citations

Jan 1, 1991·Archives of Dermatological Research·S Imai
Aug 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·U Holzer-PetscheF Lembeck
Dec 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·W Piotrowski, J C Foreman
Mar 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·C M LeeB E Sandberg
Mar 1, 1983·Naunyn-Schmiedeberg's Archives of Pharmacology·G SkofitschF Lembeck
Sep 1, 1992·Neurochemical Research·D Johnson, W Krenger
Apr 1, 1982·Agents and Actions·F Erjavec
Apr 1, 1983·Agents and Actions·J Foreman, C Jordan
Jul 1, 1996·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·H InoueY Koshihara
Jan 1, 1996·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·M DuxF K Pierau
Jun 1, 1996·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·H InoueY Koshihara
Sep 15, 1985·Biochemical Pharmacology·T B CasaleM Kaliner
Mar 23, 1984·European Journal of Pharmacology·J MizrahiD Regoli
Jul 31, 1985·European Journal of Pharmacology·R Gamse, A Saria
Oct 29, 1985·European Journal of Pharmacology·P DevillierD Regoli
Aug 16, 1991·European Journal of Pharmacology·M P RechtmanA L Boura
May 31, 1982·Life Sciences·S H BuckT F Burks
Jan 1, 1988·Pharmacology & Therapeutics·L A Chahl
Jun 19, 1984·Biochimica Et Biophysica Acta·R T JensenJ D Gardner
Jul 30, 1985·Biochimica Et Biophysica Acta·H ShibataK Tasaka
Nov 1, 1990·Peptides·D LortonD L Felten
May 1, 1993·General Pharmacology·J Donnerer, R Amann
Aug 1, 1983·Neuroscience·F Roberts, C R Calcutt
May 1, 1996·Journal of Lipid Mediators and Cell Signalling·J M Herbert, A Bernat
Aug 27, 1997·European Journal of Pharmacology·H InoueY Koshihara
Feb 1, 1997·Progress in Neurobiology·C HildebrandM Risling
May 1, 1997·Neuroscience·N DmitrievaS B McMahon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.